Schuurhuis G J, Pinedo H M, Broxterman H J, van Kalken C K, Kuiper C M, Lankelma J
Free University Hospital, Dept. of Medical Oncology, Amsterdam, The Netherlands.
Int J Cancer. 1990 Aug 15;46(2):330-6. doi: 10.1002/ijc.2910460232.
Calcium channel blockers, calmodulin inhibitors, and some other classes of non-related compounds reverse multi-drug resistance. In the present study, we found that several resistance modifiers are more toxic for MDR cells than for the corresponding sensitive parent cells, whereas others show the opposite effect. Several calcium channel blockers including bepridil, diltiazem, nifedipine and verapamil, as well as the calmodulin inhibitor trifluoperazine, were more toxic for several MDR cell lines than for the parent cell lines. In contrast, cross-resistance for cyclosporin A and the verapamil analogue Ro II-2933/001 was observed in the MDR/sensitive cell couple CHRC5/AUXB1, probably due to a concentration-dependent stimulation of cell growth in the range of 0-4 microM cyclosporin A and of 1-4 microM Ro II-2933/001. In partially revertant CHRC5 cells, growth inhibition by Ro II-2933/001 at concentrations below I microM, as seen in CHRC5 cells, changed into growth stimulation, and the collateral sensitivity to verapamil and bepridil disappeared almost completely. In the MDR cells CHRC5, 2780AD and DC3F/DMXX, cross-resistance to another calcium channel blocking agent, Ro II-1781/001 (tiapamil), was observed as well. This compound showed exceptional behavior: it induced marked potentiation of Dx cytotoxicity as well as stimulation of Dx accumulation in AUXB1 cells, even at low tiapamil concentrations, but not in the CHRC5 cells, even at high concentrations. It is concluded that resistance modifiers can selectively influence growth of MDR cells via more than one process, and resulting in either strong growth inhibition in MDR cells relative to the effect on sensitive cells or in growth stimulation.
钙通道阻滞剂、钙调蛋白抑制剂以及其他一些不相关的化合物类别可逆转多药耐药性。在本研究中,我们发现几种耐药性调节剂对多药耐药细胞的毒性比对相应的敏感亲本细胞更大,而其他一些则表现出相反的效果。几种钙通道阻滞剂,包括苄普地尔、地尔硫䓬、硝苯地平和维拉帕米,以及钙调蛋白抑制剂三氟拉嗪,对几种多药耐药细胞系的毒性比对亲本细胞系更大。相比之下,在多药耐药/敏感细胞对CHRC5/AUXB1中观察到对环孢素A和维拉帕米类似物Ro II - 2933/001的交叉耐药性,这可能是由于在0 - 4微摩尔环孢素A和1 - 4微摩尔Ro II - 2933/001范围内细胞生长受到浓度依赖性刺激。在部分回复的CHRC5细胞中,Ro II - 2933/001在低于1微摩尔浓度时对细胞生长的抑制作用(如在CHRC5细胞中所见)转变为生长刺激作用,并且对维拉帕米和苄普地尔的旁系敏感性几乎完全消失。在多药耐药细胞CHRC5、2780AD和DC3F/DMXX中,也观察到对另一种钙通道阻滞剂Ro II - 1781/001(替帕米)的交叉耐药性。该化合物表现出异常行为:即使在低替帕米浓度下,它也能显著增强阿霉素的细胞毒性以及促进阿霉素在AUXB1细胞中的积累,但在CHRC5细胞中,即使在高浓度下也无此作用。得出的结论是,耐药性调节剂可通过多种过程选择性地影响多药耐药细胞的生长,并导致相对于对敏感细胞的影响,多药耐药细胞出现强烈的生长抑制或生长刺激。